Avanir Pharmaceuticals (AVNR) Tops Q2 EPS by 2c, Revenue Falls Well Short
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Financial Fact:
Research and development: 12.3M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Research and development: 12.3M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $2.75 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
